Functional Recovery Program for Depression and Suicide Risk (RECONCILE)

The SURVIVE 2 Project: An Extended Cohort Study to Investigate Suicidal Behavior in Spain and the Efficacy of Secondary Prevention Strategies: iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)

Not applicable Interventional Hospital Clinic of Barcelona · NCT05655390

This study tests a 12-week telehealth group program designed to help adults who recently attempted suicide and have depression improve daily functioning, emotion regulation, and cognitive control.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment120 (estimated)
Ages18 Years and up
SexAll
SponsorHospital Clinic of Barcelona Academic / other
Drugs / interventionsradiation
Locations4 sites (Barcelona, Barcelona and 3 other locations)
Trial IDNCT05655390 on ClinicalTrials.gov

What this trial studies

RECONCILE is a multicenter, rater-blinded randomized trial in Spain that randomizes adults with recent suicide attempts to treatment-as-usual (TAU) or TAU plus a 12-week structured telematic group program. The group program delivers 12 weekly 90-minute sessions led by two trained therapists and combines Acceptance and Commitment Therapy with elements of CBT, DBT, psychoeducation, and an individualized safety plan. Outcomes include psychosocial functioning, cognition (decision-making, inhibition, attention), quality of life, clinical status, and neuroimaging correlates focused on the orbitofrontal and dorsal prefrontal cortices, with assessments at baseline, post-intervention, and 12-month follow-up. The study also enrolls comparison cohorts of depressed patients without recent attempts and healthy controls at one site to contextualize findings.

Who should consider this trial

Good fit: Adults over 18 with depression who have attempted suicide within the prior 10 days, can give informed consent, have no MRI contraindications, and have not received structured psychological interventions or ECT in the past 6 months are ideal candidates.

Not a fit: Patients with IQ below 70, major neurological conditions or recent head trauma, those unable to consent or participate in telematic group sessions, or those who received recent structured psychotherapy or ECT may not benefit from this program.

Why it matters

Potential benefit: If successful, the program could improve patients' ability to perform daily activities and reduce ongoing suicide risk by strengthening emotion regulation and functional skills.

How similar studies have performed: Therapies that include ACT and DBT components have shown benefits for suicidal behavior and emotion regulation, but this particular combined telematic group program targeting early post-attempt functional recovery is relatively novel and not extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age over 18 years old
* Having attempted suicide
* Provide written informed consent
* No claustrophobia/metallic objects/implants

Exclusion Criteria:

* Intelligence quotient below 70 and impaired functioning
* Any medical condition that could affect neuropsychological performance (such as neurological diseases) or a history of head trauma with loss of consciousness
* Participation in any structured psychological intervention within the past 6 months
* Patients who received electroconvulsive therapy within the past 6 months
* Inability to give inform consent

Where this trial is running

Barcelona, Barcelona and 3 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Suicide, AttemptedFunctioning, PsychosocialCognitionNeuroimagingQuality of Liftesuicidecognitionneuroimaging
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.